CA
NZ
UK
AU
IND
US
…
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of aesthetic medicines and therapeutic products. It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operating investment firms; providing packaging solutions to industrial and consumer markets; and design and production of high-tolerance components for industrial and technological applications. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Elevai Labs, Inc. (NASDAQ: ELAB) is a publicly listed technology company with limited detailed disclosures about its operations and products. Public filings and materials indicate a focus on artificial intelligence and data-driven solutions; long-term growth may depend on product commercialization, customer adoption, and successful scaling of recurring revenue, which could support investor interest if execution progresses.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-09-30 | 2022-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-09-30 | 2022-12-31 |
| Income before tax | -7.75M | -4.02M | -4.30M | -4.30M | -1.80M |
| Net income | -7.71M | -6.25M | -4.30M | -4.30M | -1.80M |
| Selling general administrative | 1.42M | 0.56M | 3.37M | 4.03M | 1.73M |
| Selling and marketing expenses | 0.20M | 0.29M | 0.66M | - | - |
| Gross profit | 0.07M | 1.80M | 1.13M | 1.13M | 0.45M |
| Reconciled depreciation | 0.10M | 0.01M | 0.01M | 0.01M | 0.01M |
| Ebit | -7.38M | -3.28M | -4.28M | - | - |
| Ebitda | -7.27M | -3.20M | -4.27M | - | - |
| Depreciation and amortization | 0.11M | 0.08M | 0.01M | - | - |
| Operating income | -7.38M | -1.87M | -3.76M | -3.76M | -1.79M |
| Other operating expenses | 7.97M | 4.33M | 5.47M | - | - |
| Interest expense | 0.55M | 0.74M | 0.02M | 0.02M | 0.00M |
| Tax provision | 0.03M | 0.00M | - | - | - |
| Interest income | 0.12M | 0.01M | 0.01M | 0.01M | 0.01M |
| Net interest income | -0.43M | -0.72M | -0.01M | -0.01M | 0.01M |
| Income tax expense | 0.03M | - | 0.00M | - | - |
| Total revenue | 0.59M | 2.47M | 1.71M | 1.71M | 0.77M |
| Total operating expenses | 7.45M | 3.66M | 4.89M | 5.47M | 2.55M |
| Cost of revenue | 0.52M | 0.67M | 0.58M | 0.58M | 0.32M |
| Total other income expense net | -0.37M | -2.15M | -0.54M | -0.53M | -0.02M |
| Net income from continuing ops | -7.78M | -4.02M | -4.30M | -4.30M | -1.80M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-09-30 | 2022-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-09-30 | 2022-12-31 |
| Total assets | 12.87M | 8.99M | 5.19M | 5.19M | 1.89M |
| Intangible assets | 2.89M | 2.80M | - | - | - |
| Other current assets | 1.03M | 2.06M | 1.06M | - | - |
| Total liab | 5.03M | 2.33M | 1.36M | 1.36M | 0.76M |
| Total stockholder equity | 7.84M | 6.66M | 3.83M | 3.83M | 1.13M |
| Other current liab | 2.36M | 1.32M | 0.52M | 0.37M | 0.07M |
| Common stock | 0.00M | 0.00M | 0.00M | - | - |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -21.02M | -13.27M | -7.02M | -7.02M | -2.72M |
| Good will | 0.98M | 0.00M | - | - | - |
| Other assets | - | - | 0.00M | - | - |
| Cash | 5.40M | 3.98M | 3.33M | 3.33M | 1.15M |
| Total current liabilities | 3.94M | 1.80M | 1.30M | 1.30M | 0.59M |
| Current deferred revenue | - | - | 0.04M | - | - |
| Net debt | -2.76M | -3.98M | -3.12M | - | - |
| Short term debt | 1.59M | - | 0.14M | - | - |
| Short long term debt | 1.34M | - | - | - | - |
| Short long term debt total | 2.64M | - | 0.21M | - | - |
| Other stockholder equity | 28.86M | 19.93M | 10.85M | - | - |
| Total current assets | 6.87M | 6.05M | 4.92M | 4.92M | 1.55M |
| Long term investments | 0.00M | 0.14M | 0.00M | - | - |
| Short term investments | 0.57M | 0.00M | - | - | - |
| Net receivables | 0.34M | 0.01M | 0.04M | 0.03M | 0.00M |
| Long term debt | 0.09M | - | - | - | - |
| Inventory | 0.10M | 0.00M | 0.50M | 0.50M | 0.23M |
| Accounts payable | 0.70M | 0.48M | 0.60M | 0.60M | 0.22M |
| Accumulated other comprehensive income | -0.00M | -0.00M | 0.00M | - | - |
| Non currrent assets other | - | 0.14M | 0.01M | - | - |
| Non current assets total | 6.00M | 2.94M | 0.27M | 0.27M | 0.34M |
| Capital lease obligations | 1.22M | 0.00M | 0.21M | 0.21M | 0.28M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-09-30 | 2022-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-09-30 | 2022-12-31 |
| Investments | -0.03M | -0.61M | -0.01M | -0.01M | -0.03M |
| Total cashflows from investing activities | -2.77M | -0.61M | -0.01M | - | - |
| Net borrowings | 0.00M | -0.24M | 0.00M | - | - |
| Total cash from financing activities | 10.12M | 6.76M | 6.74M | 6.74M | 2.36M |
| Net income | -7.75M | -6.25M | -4.30M | -4.30M | -1.80M |
| Change in cash | 1.42M | 0.66M | 2.17M | 2.17M | 0.74M |
| Begin period cash flow | 3.98M | 3.33M | 1.15M | 1.15M | 0.41M |
| End period cash flow | 5.40M | 3.98M | 3.33M | 3.33M | 1.15M |
| Total cash from operating activities | -5.93M | -5.49M | -4.56M | -4.56M | -1.59M |
| Issuance of capital stock | 2.92M | 6.99M | 7.46M | 7.46M | 2.15M |
| Depreciation | 0.10M | 0.01M | 0.01M | 0.01M | 0.01M |
| Other cashflows from investing activities | -0.69M | -0.46M | - | - | - |
| Change to inventory | 0.15M | -0.40M | -0.27M | -0.27M | -0.07M |
| Change to account receivables | -0.10M | -0.01M | -0.02M | - | - |
| Sale purchase of stock | -0.00M | 0.00M | - | - | - |
| Other cashflows from financing activities | 3.99M | 6.76M | -0.72M | - | - |
| Capital expenditures | 0.45M | 0.01M | 0.01M | 0.01M | 0.04M |
| Change in working capital | 0.59M | 0.25M | -0.82M | -0.82M | 0.01M |
| Stock based compensation | -0.02M | 0.10M | 0.49M | 0.49M | 0.17M |
| Other non cash items | 1.12M | 0.40M | 0.07M | -0.00M | 0.01M |
| Free cash flow | -6.38M | -5.49M | -4.57M | -4.57M | -1.62M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
|---|---|---|---|---|---|---|---|
| ELAB Elevai Labs, Inc. Common Stock |
-0.01 0.38% |
2.63 | - | - | 1.51 | 0.22 | 0.06 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 |
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of aesthetic medicines and therapeutic products. It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operating investment firms; providing packaging solutions to industrial and consumer markets; and design and production of high-tolerance components for industrial and technological applications. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.
120 Newport Center Drive, Newport Beach, CA, United States, 92660
866 445 4886
32
| Name | Title | Year Born |
|---|---|---|
| Dr. Jordan R. Plews Ph.D. | Co-Founder, President, CEO & Director | 1984 |
| Ms. Brenda Buechler | Chief Marketing Officer | 1971 |
| Mr. Christoph Kraneiss | Chief Commercial Officer | 1972 |
| Dr. Hatem Abou-Sayed F.A.C.S., FACS, M.B.A., M.D., MBA | Co-Founder, Chief Medical Officer & Director | 1972 |
| Mr. Graydon Bensler C.F.A. | CFO, Secretary & Director | 1992 |
| Mr. Graydon Bensler C.F.A. | CEO, CFO, Secretary & Director | 1992 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...